Financial Performance - The company's operating revenue for Q1 2023 was ¥168,238,991.99, representing a year-on-year increase of 12.06%[4] - The net profit attributable to shareholders was -¥323,774,631.80, and the net profit after deducting non-recurring gains and losses was -¥331,792,406.63[4] - The company reported a net loss of CNY 322,166,168.74 for Q1 2023, compared to a loss of CNY 282,670,647.07 in Q1 2022, indicating a worsening of about 14.0%[16] - Total comprehensive income for Q1 2023 was -326,630,103.58 RMB, compared to -287,615,486.11 RMB in Q1 2022, reflecting a decline of about 13.6% year-over-year[17] - Basic and diluted earnings per share were both -¥0.60[5] - Basic and diluted earnings per share for Q1 2023 were both -0.60 RMB, slightly worse than -0.59 RMB in Q1 2022[17] Cash Flow - The net cash flow from operating activities was -¥349,845,397.38[4] - Cash inflows from operating activities totaled 224,413,979.30 RMB in Q1 2023, up from 115,680,554.56 RMB in Q1 2022, representing an increase of approximately 93.9%[19] - Cash outflows from operating activities amounted to 574,259,376.68 RMB in Q1 2023, compared to 466,158,621.88 RMB in Q1 2022, an increase of about 23.2%[19] - The net cash flow from operating activities was -349,845,397.38 RMB in Q1 2023, slightly improved from -350,478,067.32 RMB in Q1 2022[19] - Cash and cash equivalents decreased to CNY 1,250,643,639.07 as of March 31, 2023, down from CNY 2,187,326,306.04 at the end of 2022, a decline of approximately 42.7%[14] - Cash and cash equivalents at the end of Q1 2023 were 1,086,332,437.19 RMB, down from 3,735,640,216.30 RMB at the end of Q1 2022, a decrease of approximately 70.1%[19] - The company reported cash inflows from investment activities of 68,289,252.05 RMB in Q1 2023, with cash outflows totaling 652,378,663.59 RMB, resulting in a net cash flow from investment activities of -584,089,411.54 RMB[19] - The company did not report any cash inflows from financing activities in Q1 2023, contrasting with significant inflows of -2,612,462,448.00 RMB in the same period of the previous year[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,678,394,849.53, a decrease of 5.69% compared to the end of the previous year[5] - Total assets as of March 31, 2023, were CNY 5,678,394,849.53, down from CNY 6,021,189,680.87 at the end of 2022, representing a decrease of about 5.7%[15] - The total liabilities decreased to CNY 997,690,914.23 as of March 31, 2023, from CNY 1,040,890,051.43 at the end of 2022, a reduction of approximately 4.1%[15] - The equity attributable to shareholders decreased by 6.02% to ¥4,680,703,935.30 compared to the end of the previous year[5] - The company’s total equity attributable to shareholders was CNY 4,680,703,935.30 as of March 31, 2023, down from CNY 4,980,299,629.44 at the end of 2022, a decrease of about 6.0%[15] Research and Development - Research and development expenses totaled ¥249,722,218.25, accounting for 148.43% of operating revenue, an increase of 3.11 percentage points year-on-year[5] - Research and development expenses for Q1 2023 were CNY 249,722,218.25, up from CNY 218,173,558.62 in Q1 2022, reflecting a rise of approximately 14.5%[16] - The company plans to continue focusing on R&D and market expansion strategies to improve future performance[16] Shareholder Information - The company had a total of 8,017,774.83 shares outstanding at the end of the reporting period[7] - The top shareholder, HKSCC NOMINEES LIMITED, held 34.83% of the shares, totaling 189,566,228 shares[8] - The number of common shareholders as of the reporting date was 5,654, with 5,628 A-share and 26 H-share shareholders[12] Accounting Practices - The company has not adopted new accounting standards for the year 2023, indicating continuity in financial reporting practices[20]
荣昌生物(688331) - 2023 Q1 - 季度财报